• Values and Commitments
  • Code of Conduct
  • Lobbying and Political Contributions
  • Patient and Medical Group Transparency
  • Ethical Sales and Marketing
  • HIV/AIDS Workplace Policy
  • Stem Cell Research
  • Laboratory Animals
  • Corporate Responsibility Report
  • UN Global Compact
• Global Health
• Community Programs
• U.S. Patient Assistance Programs
• Medicine Safety
• Environment Health and Safety
• Diversity
• Education

Improved Patient and Medical Group Transparency

We continue to take significant steps to improve our transparency in how we partner with patient and medical organizations.

Patient and medical groups carry out valuable work to improve the lives of people with a particular disease or medical condition. They often look to industry partners to provide financial support and other skills for their activities. This is one way we contribute to the improvement of patients’ lives beyond our core business of developing innovative medicines. For example:

• In the United Kingdom
  
  In the UK we are required, as a member of the Association of the British Pharmaceutical Industry, to publish a list of the patient organizations with whom we work. As part of our commitment to working with these groups in an open and transparent way, Pfizer UK has gone beyond the UK Industry code and described the full nature of our relationships with these groups, as noted on our website at www.pfizer.co.uk/template4.asp?pageid=392
• In the United States
  
  In the US in 2008 we will develop a disclosure plan for educational grants and include stakeholders in our planning process. This will ensure stakeholders’ views are considered as the reporting process is developed. Continuing medical education, sponsored by these grants, provides educational opportunities to physicians and other healthcare professionals that help them to improve patient care. To learn more please see www.pfizermededgrants.com